Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
NIHCM GRANTS
By Ola Abdelhadi
By Richard Scheffler
University California at Berkley
***
***
Despite increases in private equity acquisition of oncology practices, little is known about the effect on market competition, prices, and quality.
CITE: https://www.r2library.com/Resource/Title/0826102549
This research team will examine the changes in health care quality and prices following private equity acquisition of oncology practices and explore whether these acquisitions exacerbate health disparities among racial groups. This work may be relevant to policymakers and antitrust regulators assessing private equity deals.
***
COMMENTS APPRECIATED
Thank You
***
***
Share this:
Filed under: "Doctors Only", Career Development, Drugs and Pharma, Health Economics, Health Insurance, Information Technology, Insurance Matters, Investing | Tagged: cancer, cancer care, grants, NIHCM, NIHCM Grants, Ola Abdelhadi, Oncology, oncology care, Private Equity, Richard Scheffler |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
ADVANCES
There’s a new way to screen for some cancers. Scientists in South Korea have developed a cheap way to detect pancreatic and prostate cancer—and all the patient has to do is pee on a strip.
They say their sensor, which costs around eight cents, has a 99% success rate in identifying the urine of people with these cancers versus people without. And the team is experimenting further to try to extend it to more cancers, including colon-rectal and lung cancers.
Diane
LikeLike